Skip to main content

Table 3 Antipsychotic treatment, route of distribution and substance by proportion of patients with dispensed prescription in 2012

From: Health care use, drug treatment and comorbidity in patients with schizophrenia or non-affective psychosis in Sweden: a cross-sectional study

  Schizophrenia (%) NAP (%) RR 95% CI
Antipsychotic medication (N = 7284) (N = 11,485)   
Per orala 55.5 41.9 1.32 1.29–1.36
Long-term injectablesa 10.3 2.05 5.01 4.35–5.79
Per oral and long-term injectablesa 12.5 2.9 4.26 3.78–4.81
No antipsychotic medicationa 21.6 53.1 0.41 0.39–0.43
Substance Schizophrenia (%) NAP (%) RR 95% CI  
 Olanzapinea 21.4 16.4 1.33 1.25–1.41
 Zuclopenthixola 14.1 3.3 4.24 3.78–4.75
 Risperidonea 12.9 9.9 1.30 1.20–1.41
 Perphenazinea 12.8 4.7 2.72 2.45–3.01
 Haloperidola 12.6 6.4 1.95 1.78–2.14
 Clozapinea 11.6 1.2 9.63 8.06–11.50
 Aripiprazolea 9.2 6.0 1.54 1.39–1.70
 Quetiapinea 7.1 8.2 0.86 0.78–0.95
 Flupentixola 3.9 2.7 1.42 1.21–1.66
 Paliperidonea 3.8 1.3 2.92 2.40–3.56
 Ziprasidone 1.4 1.0 1.30 1.00–1.69
 Chlorprothixene 0.8 0.06 1.33 0.93–1.91
 Fluphenazinea 0.3 0.05 6.31 2.58–15.42
 Melperone 0.2 0.1 1.58 0.79–3.15
 Thioridazine 0.1 0.05 2.36 0.84–6.64
 Chlorpromazinea 0.1 0.02 6.31 1.34–29.69
 Sertindole 0.06 0.02 3.15 0.58–17.21
 Sulpiride 0.04 0   
 Cyamemazine 0.01 0   
 Pimozide 0.01 0   
  1. aStatistically significant difference between patient groups (95% CI for RR)